Vir Biotechnology (VIR) EBT (2018 - 2026)
Vir Biotechnology (VIR) posted EBT of -$125.5 million for Q1 2026, down 191.51% sequentially from -$43.1 million in Q4 2025, and down 3.78% YoY from -$130.5 million in Q1 2025.
Vir Biotechnology (VIR) EBT (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported EBT for 9 years, with the latest figure at -$125.5 million in Q1 2026.
- Quarterly EBT fell 3.78% year-over-year to -$125.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$442.3 million (up 23.61% YoY) and the FY2025 annual result came in at -$437.8 million, up 16.31% from the prior year.
- EBT declined to -$125.5 million in Q1 2026 per VIR's latest filing, from -$43.1 million in the prior quarter.
- Over five years, EBT peaked at $921.9 million in Q1 2022 and troughed at -$233.7 million in Q2 2022.
- A 5-year average of -$56.5 million and a median of -$125.5 million in 2026 frame the typical range for EBT.
- The widest YoY moves for EBT: up 646.43% in 2022, down 477.79% in 2022.
- Over 5 years, EBT stood at -$151.6 million in 2022, then grew by 20.36% to -$120.8 million in 2023, then increased by 13.32% to -$104.7 million in 2024, then surged by 58.86% to -$43.1 million in 2025, then sank by 191.51% to -$125.5 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$125.5 million, -$43.1 million, and -$163.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 80.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.26 Mn |
| Mar 31, 2026 | -125.53 Mn |
| Dec 31, 2025 | -43.06 Mn |
| Sep 30, 2025 | -162.97 Mn |
| Jun 30, 2025 | -110.79 Mn |
| Mar 31, 2025 | -120.95 Mn |
| Dec 31, 2024 | -104.68 Mn |
| Sep 30, 2024 | -213.54 Mn |
| Jun 30, 2024 | -139.89 Mn |
| Mar 31, 2024 | -65.00 Mn |
| Dec 31, 2023 | -120.76 Mn |
| Sep 30, 2023 | -166.63 Mn |
| Jun 30, 2023 | -197.62 Mn |
| Mar 31, 2023 | -143.19 Mn |
| Dec 31, 2022 | -151.64 Mn |
| Sep 30, 2022 | 217.73 Mn |
| Jun 30, 2022 | -233.72 Mn |
| Mar 31, 2022 | 921.91 Mn |
| Dec 31, 2021 | 545.89 Mn |
| Sep 30, 2021 | 110.76 Mn |